Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis ( ...
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) - Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis ( A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan ...